{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T19:28:30Z","timestamp":1772479710879,"version":"3.50.1"},"reference-count":23,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["J Med Ethics"],"accepted":{"date-parts":[[2026,2,13]]},"abstract":"<jats:p>Cystic fibrosis (CF) is a life-limiting genetic disease frequently associated with pancreatic insufficiency (PI), traditionally considered irreversible. CF transmembrane conductance regulator modulators such as elexacaftor\/tezacaftor\/ivacaftor (ETI; Trikafta) have transformed CF care yet remain FDA-approved only for children aged 2 years and older. We present the case of a 9-month-old female with CF and PI whose mother, highly health-literate and resourceful, pursued early ETI exposure through breastmilk transfer and later direct off-label dosing, despite medical guidance and regulatory restrictions. Remarkably, the child achieved pancreatic sufficiency, discontinued pancreatic enzyme replacement therapy and showed no evidence of hepatic or ophthalmologic toxicity.<\/jats:p>\n                  <jats:p>This case raises significant ethical questions: What constitutes an appropriate physician\u2019s response when parents pursue unapproved but plausibly effective therapies? Should monitoring and harm reduction be seen as ethically permissible, or should stronger discouragement\u2014including refusal of guidance or child protective intervention\u2014be considered? Using an adapted risk\u2013benefit framework derived from complementary and complementary medicine ethics, we argue that the medical team\u2019s approach\u2014recommending standard of care while monitoring for safety and efficacy\u2014was ethically justifiable harm reduction in light of the mother\u2019s persistence, the plausible biological rationale and early positive outcomes. We further explore how this assessment may shift when FDA-approved alternatives become available and compare this case to analogous dilemmas such as paediatric stem cell tourism. Ultimately, we suggest that calibrated physician responses, scaled to the degree of risk and potential benefit, best serve the child\u2019s interests in ethically ambiguous contexts of parental pursuit of unproven but potentially beneficial treatments.<\/jats:p>","DOI":"10.1136\/jme-2025-111365","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:25:22Z","timestamp":1772475922000},"page":"jme-2025-111365","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Harm reduction in paediatric off-label therapy: ethical analysis of early CFTR modulator use in an infant with cystic fibrosis"],"prefix":"10.1136","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0655-2055","authenticated-orcid":false,"given":"Alex","family":"Gariti","sequence":"first","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Johnson","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siby","family":"Moonnumakal","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frank","family":"Placencia","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kimberly","family":"Sawyer","sequence":"additional","affiliation":[{"name":"Pediatrics, Baylor College of Medicine, Houston, Texas, USA"},{"name":"Palliative Care, Texas Children\u2019s Hospital, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David G","family":"Mann","sequence":"additional","affiliation":[{"name":"Baylor College of Medicine, Houston, Texas, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"key":"2026030210251571000_jme-2025-111365v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2216474"},{"key":"2026030210251571000_jme-2025-111365v1.2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcf.2017.06.011"},{"key":"2026030210251571000_jme-2025-111365v1.3","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1016\/j.jpeds.2012.10.008","article-title":"Evolution of pancreatic function during the first year in infants with cystic fibrosis","volume":"162","author":"O\u2019Sullivan","year":"2013","journal-title":"J Pediatr"},{"key":"2026030210251571000_jme-2025-111365v1.4","unstructured":"Professional, Cleveland Clinic medical . \u201cExocrine pancreatic insufficiency (epi): pancreatitis. Available: https:\/\/my.clevelandclinic.org\/health\/diseases\/21577-exocrine-pancreatic-insufficiency-epi [Accessed 29 May 2024]."},{"key":"2026030210251571000_jme-2025-111365v1.5","unstructured":"TRIKAFTA\u00ae (Elexacaftor\/Tezacaftor\/Ivacaftor and Ivacaftor) . How does TRIKAFTA\u00ae work?\u201d how it works. Available: www.trikafta.com\/how-trikafta-works [Accessed 29 May 2024]."},{"key":"2026030210251571000_jme-2025-111365v1.6","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/j.jcf.2025.01.012","article-title":"Monitoring ETI effects over 1.7 years in an infant treated in utero, via breast milk and granules by repeated faecal elastase measurements","volume":"24","author":"Appelt","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026030210251571000_jme-2025-111365v1.7","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.jcf.2025.08.006","article-title":"Successful off-label use of elexacaftor\/tezacaftor\/ivacaftor in an infant with severe CF disease","volume":"24","author":"Shevill","year":"2025","journal-title":"J Cyst Fibros"},{"key":"2026030210251571000_jme-2025-111365v1.8","article-title":"A Review of TRIKAFTA: Triple Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulator Therapy","volume":"13","author":"Zaher","year":"2021","journal-title":"Cureus"},{"key":"2026030210251571000_jme-2025-111365v1.9","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1275470","article-title":"Efficacy and safety profile of elexacaftor-tezacaftor-ivacaftor triple therapy on cystic fibrosis: a systematic review and single arm meta-analysis","volume":"14","author":"Xu","year":"2023","journal-title":"Front Pharmacol"},{"key":"2026030210251571000_jme-2025-111365v1.10","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1080\/17476348.2023.2179989","article-title":"Managing cystic fibrosis in children aged 6-11yrs: a critical review of elexacaftor\/tezacaftor\/ivacaftor combination therapy","volume":"17","author":"Jordan","year":"2023","journal-title":"Expert Rev Respir Med"},{"key":"2026030210251571000_jme-2025-111365v1.11","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal Cystic Fibrosis Transmembrane Conductance Regulator Modulator Therapy: A Promising Way to Change the Impact of Cystic Fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"key":"2026030210251571000_jme-2025-111365v1.12","unstructured":"Center for Drug Evaluation and Research . IND applications for clinical treatment (expanded access): overview. U.S. Food and Drug Administration. Available: www.fda.gov\/drugs\/investigational-new-drug-ind-application\/ind-applications-clinical-treatment-expanded-access-overview#:~:text=Expanded%20access%2C%20sometimes%20called%20%22compassionate%20use%2C%22%20is%20the,are%20no%20comparable%20or%20satisfactory%20alternative%20treatment%20options [Accessed 29 May 2024]."},{"key":"2026030210251571000_jme-2025-111365v1.13","unstructured":"Staff RT . TRIKAFTA approved by FDA for cystic fibrosis. Respiratory Therapy. 2025. Available: https:\/\/respiratory-therapy.com\/products-treatment\/pharmaceuticals\/us-pharmaceuticals\/trikafta-approved-by-fda-for-cystic-fibrosis\/"},{"key":"2026030210251571000_jme-2025-111365v1.14","doi-asserted-by":"crossref","DOI":"10.3390\/jcm9092706","article-title":"CFTR Modulators: Impact on Fertility, Pregnancy, and Lactation in Women with Cystic Fibrosis","volume":"9","author":"Taylor-Cousar","year":"2020","journal-title":"J Clin Med"},{"key":"2026030210251571000_jme-2025-111365v1.15","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking Elexacaftor, Tezacaftor, and Ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"2026030210251571000_jme-2025-111365v1.16","doi-asserted-by":"crossref","first-page":"3377","DOI":"10.1002\/ppul.26706","article-title":"Use of CFTR modulators in special populations, part 1: Pregnancy and lactation","volume":"58","author":"Elijah","year":"2023","journal-title":"Pediatr Pulmonol"},{"key":"2026030210251571000_jme-2025-111365v1.17","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12091528","article-title":"Trikafta-Extending Its Success to Less Common Mutations","volume":"12","author":"Bentur","year":"2022","journal-title":"J Pers Med"},{"key":"2026030210251571000_jme-2025-111365v1.18","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2017-1961","article-title":"Pediatric Integrative Medicine","volume":"140","author":"McClafferty","year":"2017","journal-title":"Pediatrics"},{"key":"2026030210251571000_jme-2025-111365v1.19","doi-asserted-by":"crossref","first-page":"660","DOI":"10.7326\/0003-4819-137-8-200210150-00010","article-title":"Ethical considerations of complementary and alternative medical therapies in conventional medical settings","volume":"137","author":"Adams","year":"2002","journal-title":"Ann Intern Med"},{"key":"2026030210251571000_jme-2025-111365v1.20","first-page":"61","article-title":"Ethics meet complementary and alternative medicine: new light on old principles","volume":"21","author":"Kemper","year":"2004","journal-title":"Contemp Pediatr"},{"key":"2026030210251571000_jme-2025-111365v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.ackd.2005.03.003"},{"key":"2026030210251571000_jme-2025-111365v1.22","doi-asserted-by":"publisher","DOI":"10.1016\/j.bpg.2010.03.006"},{"key":"2026030210251571000_jme-2025-111365v1.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1748-720X.2012.00650.x"}],"container-title":["Journal of Medical Ethics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/jme-2025-111365","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:25:25Z","timestamp":1772475925000},"score":1,"resource":{"primary":{"URL":"https:\/\/jme.bmj.com\/lookup\/doi\/10.1136\/jme-2025-111365"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":23,"alternative-id":["10.1136\/jme-2025-111365"],"URL":"https:\/\/doi.org\/10.1136\/jme-2025-111365","relation":{},"ISSN":["0306-6800","1473-4257"],"issn-type":[{"value":"0306-6800","type":"print"},{"value":"1473-4257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}